Recombinant Human CMG-2/ANTXR2 Fc Chimera Protein, CF

When Anthrax Protective Antigen is immobilized at 1.5 μg/mL (100 μL/well), Recombinant Human CMG-2/ANTXR2 Fc Chimera (Catalog # 10360-AR) binds with an ED50 of 1-6 ng/mL.

2 μg/lane of Recombinant Human CMG-2/ANTXR2 Fc Chimera (Catalog # 10360-AR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-75 kDa and 110-150 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CMG-2/ANTXR2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Anthrax Protective Antigen is immobilized at 1.5 μg/mL (100 μL/well), it binds Recombinant Human CMG‑2/ANTXR2 Fc Chimera (Catalog # 10360-AR) with an ED₅₀ of 1-6 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CMG-2/ANTXR2 protein
  

  Human CMG-2/ANTXR2 (Gln34-Asn317) Accession # P58335.5	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: P58335
• N-terminal Sequence: Gln34 inferred from enzymatic pyroglutamate treatment revealing Glu35
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 57 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-75 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CMG-2/ANTXR2 Fc Chimera Protein, CF

• anthrax toxin receptor 2
• ANTXR2
• Capillary morphogenesis gene 2 protein
• capillary morphogenesis protein 2
• cI-35
• CMG2
• CMG-2
• CMG2MGC111533
• CMG-2MGC45856
• FLJ31074
• ISH
• JHF
• JHS

Background

Capillary Morphogenesis Gene-2 (CMG-2) is a widely expressed anthrax toxin receptor (ATR) family protein (1 - 3). CMG-2 is a 55 kDa type I transmembrane (TM) protein that contains a 33 amino acid (aa) signal sequence, a 284 aa extracellular domain (ECD), a 24 aa TM segment, and a 147 aa cytoplasmic domain. There are three additional isoforms. Isoforms 4 shows a 12 aa insertion in the cytoplasmic region; isoform 2 shows a 103 aa deletion in the ECD; and isoform 3 is a truncated, 20 kDa, 289 aa soluble form. The main functional domain of CMG-2 is an extracellular integrin-like von Willebrand factor type A (VWA) domain with a metal ion dependent adhesion site (MIDAS). This domain adheres selectively to collagen type IV and laminin (1 - 5). CMG-2 isoform 2 is induced in HUVEC as they undergo capillary formation in collagen matrices in vitro (3). CMG-2 is mutated in juvenile hyaline fibromatosis and infantile systemic hyalinosis disorders, and several of these mutations result in loss of laminin binding (6). CMG-2 and the related protein ATR/TEM8 serve as receptors for the protective antigen (PA) of Bacillus Anthracis (1, 2). After binding the VWA domain, PA undergoes furin-type cleavage, forms a heptameric receptor/PA pre-pore and binds LF or EF toxin subunits (5, 7, 8). Transport to low pH endosomes, which requires CMG-2 ubiquitination and interaction with the LDL receptor related protein LRP6 (9, 10), allows PA pore formation and release of toxin to the cytoplasm (10, 11). Soluble CMG-2 VWA domain acts as a dummy receptor that can protect cultured cells from anthrax intoxication (2). Within the extracellular region, human CMG-2 shares 84%, 81%,89% and 93% amino acid sequence homology with mouse, rat, bovine, and canine CMG-2, respectively. CMG-2 VWA domain also shares 60% aa identity with ATR/TEM8.

1. Scobie, H.M. and J.A.T. Young (2005) Curr. Opin. Microbiol. 8:106.
2. Scobie, H.M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:5170.
3. Bell, S.E. et al. (2001) J. Cell Sci. 114:2755.
4. Lacy, D.B. et al. (2004) Proc. Natl. Acad. Sci. USA 101:6367.
5. Santelli, E. et al. (2004) Nature 430:905.
6. Dowling, O. et al. (2003) Am. J. Hum. Genet. 73:957.
7. Wigelsworth, D.J. et al. (2004) J. Biol. Chem. 279:23349.
8. Go, M.Y. et al. (2006) J. Mol. Biol. 360:145.
9. Abrami, L. et al. (2006) J. Cell Biol. 172:309.
10. Wei, W. et al. (2006) Cell 124:1141.
11. Lacy, D.B. et al. (2004) Proc. Natl. Acad. Sci. USA 101:13147.

Bioinformatics

• Uniprot:
  • P58335()